EcoDrugPlus

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSDCDG00000022177
Gene Symbol: NTRK2B
1 Cross references
213 Possible Orthologues:

Nicastrin

Ensembl ID : ENSDCDG00000034268
Gene Symbol: NCSTN
3 Cross references
204 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSDCDG00000029144
Gene Symbol: NAMPT
3 Cross references
219 Possible Orthologues:

Nischarin

Ensembl ID : ENSDCDG00000034838
Gene Symbol: NISCH
3 Cross references
210 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSDCDG00000026754
Gene Symbol: NOS2
3 Cross references
168 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSDCDG00000021339
Gene Symbol: NFKB1
3 Cross references
202 Possible Orthologues:

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSDCDG00000034191
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSDCDG00000035058
Gene Symbol: NR1H3
3 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSDCDG00000022649
Gene Symbol: NR1H4
3 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSDCDG00000034853
Gene Symbol: NR3C1
3 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSDCDG00000026266
Gene Symbol: NR3C2
3 Cross references
211 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSDCDG00000024103
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).